Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Buc, Milan ^a  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; BETA INTERFERON; CD20 ANTIBODY; CD52 ANTIGEN; DACLIZUMAB; FINGOLIMOD; GAMMA INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MONOCLONAL ANTIBODY; NATALIZUMAB; OCRELIZUMAB; OFATIMUMAB; RITUXIMAB; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; AUTOIMMUNITY; B LYMPHOCYTE; BIOLOGICAL THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL PRACTICE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; LABORATORY TEST; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL; ANIMAL; IMMUNOLOGY; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; PROCEDURES;

ANIMALS; BIOLOGICAL THERAPY; HUMANS; MULTIPLE SCLEROSIS; T-LYMPHOCYTES, REGULATORY;

EID: 84878633653     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/963748     Document Type: Review

References (105)

1. Liu Y. J., A unified theory of central tolerance in the thymus. Trends in Immunology 2006 27 5 215 221 2-s2.0-33646162855 10.1016/j.it.2006.03.004
2. Lan R. Y., Ansari A. A., Lian Z. X., Gershwin M. E., Regulatory T cells: development, function and role in autoimmunity. Autoimmunity Reviews 2005 4 6 351 363 2-s2.0-23144450643 10.1016/j.autrev.2005.01.007 (Pubitemid 41080072)
3. Sakaguchi S., Miyara M., Costantino C. M., Hafler D. A., FOXP3 + regulatory T cells in the human immune system. Nature Reviews Immunology 2010 10 7 490 500 2-s2.0-77954141914 10.1038/nri2785
4. Josefowicz S. Z., Lu L. F., Rudensky A. Y., Regulatory T cells: mechanisms of differentiation and function. Annual Review of Immunology 2012 30 531 564
5. Park S. G., Mathur R., Long M., Hosh N., Hao L., Hayden M. S., Ghosh S., T Regulatory cells maintain intestinal homeostasis by suppressing γ δ T cells. Immunity 2010 33 5 791 803 2-s2.0-78650209225 10.1016/j.immuni.2010.10.014
6. Ohkura N., Sakaguchi S., Maturation of effector regulatory T cells. Nature Immunology 2011 12 4 283 284 2-s2.0-79952938313 10.1038/ni0411-283
7. Ouyang W., Li M. O., Foxo: in command of T lymphocyte homeostasis and tolerance. Trends in Immunology 2011 32 1 26 33 2-s2.0-78650731638 10.1016/j.it.2010.10.005
8. + regulatory T cells in the absence of interleukin 2 signaling. Nature Immunology 2005 6 11 1152 1159 2-s2.0-27544446622 10.1038/ni1264 (Pubitemid 41541793)
9. + T regulatory cell development during the neonatal period. Journal of Experimental Medicine 2005 201 5 769 777 2-s2.0-15544384475 10.1084/jem.20041179 (Pubitemid 40403028)
10. + regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. Journal of Experimental Medicine 2005 201 5 723 735 2-s2.0-15444374646 10.1084/jem.20041982 (Pubitemid 40395118)
11. Langier S., Sade K., Kivity S., Regulatory T cells: the suppressor arm of the immune system. Autoimmunity Reviews 2010 10 2 112 115 2-s2.0-78649447854 10.1016/j.autrev.2010.08.013
12. + T regulatory cell-mediated suppression. Immunity 2009 30 5 636 645 2-s2.0-65549136983 10.1016/j.immuni. 2009.04.010
13. Cvetanovich G. L., Hafler D. A., Human regulatory T cells in autoimmune diseases. Current Opinion in Immunology 2010 22 6 753 760 2-s2.0-78649897032 10.1016/j.coi.2010.08.012
14. + Regulatory T Cells increases at multiple sclerosis relapse: sex differences. International Journal of Molecular Sciences 2012 13 6 6698 6710
15. + regulatory T cells. Current Opinion in Immunology 2010 22 5 575 582 2-s2.0-78049318852 10.1016/j.coi.2010.08.004
16. Josefowicz S. Z., Niec R. E., Kim H. Y., Treuting P., Chinen T., Zheng Y., Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature 2012 482 7385 395 399
17. + regulatory T cells in immune tolerance. Annual Review of Immunology 2012 30 733 758
18. Knippenberg S., Peelen E., Smolders J., Thewissen M., Menheere P., Cohen Tervaert J. W., Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naive/memory Breg ratio during a relapse but not in remission. Journal of Neuroimmunology 2011 239 1-2 80 86
19. + T reg cells. Journal of Experimental Medicine 2012 209 10 1723 1742
20. + T cell immunity. Nature Reviews Immunology 2010 10 4 236 247 2-s2.0-77950070632 10.1038/nri2729
21. Vitale G., Mion F., Pucillo C., Regulatory B cells: evidence, developmental origin and population diversity. Molecular Immunology 2010 48 1-3 1 8 2-s2.0-78649499723 10.1016/j.molimm.2010.09.010
22. Yoshizaki A., Miyagaki T., DiLillo D. J., Matsushita T., Horikawa M., Kountikov E. I., Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 2012 491 7423 264 268
23. Sospedra M., Martin R., Immunology of multiple sclerosis. Annual Review of Immunology 2005 23 683 747 2-s2.0-17644396349 10.1146/annurev.immunol.23. 021704.115707 (Pubitemid 40563183)
24. Simon K. C., Munger K. L., Ascherio A., Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics. Current Opinion in Neurology 2012 25 3 246 251
25. Baeke F., Takiishi T., Korf H., Gysemans C., Mathieu C., Vitamin D: modulator of the immune system. Current Opinion in Pharmacology 2010 10 4 482 496 2-s2.0-77955251897 10.1016/j.coph.2010.04.001
26. Okada H., Khoury S. J., Type17 T-cells in central nervous system autoimmunity and tumors. Journal of Clinical Immunology 2012 32 4 802 808
27. Engelhardt B., Ransohoff R. M., Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends in Immunology 2012 33 12 579 589
28. Krumbholz M., Theil D., Steinmeyer F., Cepok S., Hemmer B., Hofbauer M., Farina C., Derfuss T., Junker A., Arzberger T., Sinicina I., Hartle C., Newcombe J., Hohlfeld R., Meinl E., CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. Journal of Neuroimmunology 2007 190 1-2 72 79 2-s2.0-35448986091 10.1016/j.jneuroim.2007.07.024 (Pubitemid 47625610)
29. D'Agostino P. M., Gottfried-Blackmore A., Anandasabapathy N., Bulloch K., Brain dendritic cells: biology and pathology. Acta Neuropathologica 2012 124 5 599 614
30. Becher B., Durell B. G., Miga A. V., Hickey W. F., Noelle R. J., The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. Journal of Experimental Medicine 2001 193 8 967 974 2-s2.0-0035896737 10.1084/jem.193.8.967 (Pubitemid 32525869)
31. Vogel D. Y., Vereyken E. J., Glim J. E., Heijnen P. D., Moeton M., van der Valk P., Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. Journal of Neuroinflammation 2013 10 1, article 35
32. O'Connor R. A., Prendergast C. T., Sabatos C. A., Lau C. W. Z., Leech M. D., Wraith D. C., Anderton S. M., Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. Journal of Immunology 2008 181 6 3750 3754 2-s2.0-56149125346
33. Fletcher J. M., Lalor S. J., Sweeney C. M., Tubridy N., Mills K. H. G., T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clinical and Experimental Immunology 2010 162 1 1 11 2-s2.0-77956536780 10.1111/j.1365-2249.2010.04143.x
34. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., Giuliani F., Arbour N., Becher B., Prat A., Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nature Medicine 2007 13 10 1173 1175 2-s2.0-34948909646 10.1038/nm1651 (Pubitemid 47530640)
35. Buzzard K. A., Broadley S. A., Butzkueven H., What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? International Journal of Molecular Sciences 2012 13 10 12665 12709
36. + T cells in multiple sclerosis. Annals of Neurology 2009 66 2 132 141 2-s2.0-70149122373 10.1002/ana.21744
37. Huan J., Culbertson N., Spencer L., Bartholomew R., Burrows G. G., Chou Y. K., Bourdette D., Ziegler S. F., Offner H., Vandenbark A. A., Decreased FOXP3 levels in multiple sclerosis patients. Journal of Neuroscience Research 2005 81 1 45 52 2-s2.0-23744515175 10.1002/jnr.20522 (Pubitemid 41139109)
38. Praksova P., Stourac P., Bednarik J., Vlckova E., Mikulkova Z., Michalek J., Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations. Journal of the Neurological Sciences 2012 319 1-2 18 23
39. + regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clinical and Experimental Immunology 2007 147 3 412 418 2-s2.0-33846817153 10.1111/j.1365-2249.2006.03271.x (Pubitemid 46208041)
40. +CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. European Journal of Immunology 2005 35 11 3343 3352 2-s2.0-27944499757 10.1002/eji.200526065 (Pubitemid 41672538)
41. + T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis. Journal of Neuroimmunology 2006 180 1-2 178 184 2-s2.0-33751113922 10.1016/j.jneuroim.2006. 08.003 (Pubitemid 44767710)
42. Lowther D. E., Hafler D. A., Regulatory T cells in the central nervous system. Immunological Reviews 2012 248 1 156 169
43. + regulatory T cells in human autoimmune diseases. Nature Reviews Immunology 2010 10 12 849 859 2-s2.0-78649526238 10.1038/nri2889
44. Joller N., Peters A., Anderson A. C., Kuchroo V. K., Immune checkpoints in central nervous system autoimmunity. Immunological Reviews 2012 248 1 122 139
45. Schneider-Hohendorf T., Stenner M. P., Weidenfeller C., Zozulya A. L., Simon O. J., Schwab N., Wiendl H., Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis. European Journal of Immunology 2010 40 12 3581 3590 2-s2.0-78649600894 10.1002/eji.201040558
46. + regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. Journal of Immunology 2002 169 9 4712 4716 2-s2.0-0036838536 (Pubitemid 35217131)
47. + regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America 2004 101 43 15434 15439 2-s2.0-7444250675 10.1073/pnas.0404444101 (Pubitemid 39441559)
48. Esiri M. M., Immunoglobulin containing cells in multiple sclerosis plaques. Lancet 1977 2 8036 478 480 2-s2.0-0017645154 (Pubitemid 8166586)
49. Genain C. P., Cannella B., Hauser S. L., Raine C. S., Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nature Medicine 1999 5 2 170 175 2-s2.0-0032950794 10.1038/5532 (Pubitemid 29068523)
50. Lovato L., Willis S. N., Rodig S. J., Caron T., Almendinger S. E., Howell O. W., Reynolds R., O'Connor K. C., Hafler D. A., Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain 2011 134 2 534 541 2-s2.0-79551695835 10.1093/brain/awq350
51. Magliozzi R., Howell O., Vora A., Serafini B., Nicholas R., Puopolo M., Reynolds R., Aloisi F., Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007 130 4 1089 1104 2-s2.0-34249700046 10.1093/brain/awm038 (Pubitemid 47355604)
52. Serafini B., Rosicarelli B., Magliozzi R., Stigliano E., Aloisi F., Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathology 2004 14 2 164 174 2-s2.0-2442708947 (Pubitemid 38656388)
53. Kooi E. J., Geurts J. J., van Horssen J., Bø L., van der Valk P., Meningeal inflammation is not associated with cortical demyelination in chronic multiple sclerosis. Journal of Neuropathology and Experimental Neurology 2009 68 9 1021 1028 2-s2.0-70349577131 10.1097/NEN.0b013e3181b4bf8f
54. Nylander A., Hafler D. A., Multiple sclerosis. Journal of Clinical Investigation 2012 122 4 1180 1188
55. Peelen E., Damoiseaux J., Smolders J., Knippenberg S., Menheere P., Tervaert J. W., Th17 expansion in MS patients is counterbalanced by an expanded CD39+ regulatory T cell population during remission but not during relapse. Journal of Neuroimmunology 2011 240-241 97 103
56. Varrin-Doyer M., Spencer C. M., Schulze-Topphoff U., Nelson P. A., Stroud R. M., Cree B. A., Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Annals of Neurology 2012 72 1 53 64
57. Nurieva R. I., Chung Y., Understanding the development and function of T follicular helper cells. Cellular and Molecular Immunology 2010 7 3 190 197 2-s2.0-77953273617 10.1038/cmi.2010.24
58. Lennon P. V. A., Wingerchuk D. M., Kryzer T. J., Pittock S. J., Lucchinetti C. F., Fujihara K., Nakashima I., Weinshenker B. G., A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004 364 9451 2106 2112 2-s2.0-10344250945 10.1016/S0140-6736(04)17551-X (Pubitemid 39626806)
59. Jarius S., Paul F., Franciotta D., Waters P., Zipp F., Hohlfeld R., Vincent A., Wildemann B., Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nature Clinical Practice Neurology 2008 4 4 202 214 2-s2.0-42049118701 10.1038/ncpneuro0764 (Pubitemid 351516748)
60. Li W., Minohara M., Piao H., Matsushita T., Masaki K., Matsuoka T., Isobe N., Su J. J., Ohyagi Y., Kira J. I., Association of anti-Helicobacter pylori neutrophil-activating protein antibody response with anti-aquaporin-4 autoimmunity in Japanese patients with multiple sclerosis and neuromyelitis optica. Multiple Sclerosis 2009 15 12 1411 1421 2-s2.0-72749086379 10.1177/1352458509348961
61. Ren Z., Wang Y., Duan T., Patel J., Liggett T., Loda E., Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: potential relevance to neuromyelitis optica. Journal of Immunology 2012 189 9 4602 4611
62. Uzawa A., Mori M., Arai K., Sato Y., Hayakawa S., Masuda S., Taniguchi J., Kuwabara S., Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Multiple Sclerosis 2010 16 12 1443 1452 2-s2.0-78650092261 10.1177/1352458510379247
63. Wang H. H., Dai Y. Q., Qiu W., Lu Z. Q., Peng F. H., Wang Y. G., Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. Journal of Clinical Neuroscience 2011 18 10 1313 1317
64. Papadopoulos M. C., Verkman A. S., Aquaporin 4 and neuromyelitis optica. Lancet Neurology 2012 11 6 535 544
65. Palace J., Leite M. I., Nairne A., Vincent A., Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Archives of Neurology 2010 67 8 1016 1017 2-s2.0-77955456303 10.1001/archNeurology.2010.188
66. Tradtrantip L., Zhang H., Saadoun S., Phuan P. W., Lam C., Papadopoulos M. C., Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Annals of Neurology 2012 71 3 314 322
67. Graber J. J., McGraw C. A., Kimbrough D., Dhib-Jalbut S., Overlapping and distinct mechanisms of action of multiple sclerosis therapies. Clinical Neurology and Neurosurgery 2010 112 7 583 591 2-s2.0-77955665655 10.1016/j.clineuro.2010.05.002
68. + regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis. Journal of Neuroimmunology 2012 242 1-2 39 46
69. + regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. Journal of Neuroimmunology 2007 182 1-2 204 211 2-s2.0-33845873044 10.1016/j.jneuroim.2006.09.012 (Pubitemid 46026708)
70. Burger D., Molnarfi N., Weber M. S., Brandt K. J., Benkhoucha M., Gruaz L., Chofflon M., Zamvil S. S., Lalive P. H., Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1 β in human monocytes and multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America 2009 106 11 4355 4359 2-s2.0-63149114677 10.1073/pnas.0812183106
71. Lalive P. H., Neuhaus O., Benkhoucha M., Burger D., Hohlfeld R., Zamvil S. S., Weber M. S., Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs 2011 25 5 401 414 2-s2.0-79953890862 10.2165/11588120-000000000-00000
72. +CD31+ T-cells in patients with multiple sclerosis. Journal of Neuroimmunology 2009 216 1-2 113 117 2-s2.0-71749093254 10.1016/j.jneuroim.2009.06.011
73. + regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proceedings of the National Academy of Sciences of the United States of America 2005 102 18 6449 6454 2-s2.0-18144387626 10.1073/pnas.0502187102 (Pubitemid 40617463)
74. Skarica M., Eckstein C., Whartenby K. A., Calabresi P. A., Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. Journal of Neuroimmunology 2011 235 1-2 70 76 2-s2.0-79957973246 10.1016/j.jneuroim.2011.02.010
75. Martelli A. M., Tabellini G., Bressanin D., Ognibene A., Goto K., Cocco L., The emerging multiple roles of nuclear Akt. Biochimica et Biophysica Acta 2012 1823 12 2168 2178
76. Rossi S., Motta C., Studer V., Monteleone F., De Chiara V., Buttari F., A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation. Multiple Sclerosis 2013 19 1 59 68
77. Mancini N., Clementi M., Burioni R., Natalizumab-associated progressive multifocal leukoencephalopathy. New England Journal of Medicine 2012 367 9 871 872
78. Chataway J., Miller D. H., Natalizumab therapy for multiple sclerosis. Neurotherapeutics 2013 10 1 19 28
79. Shelburne S. A., Visnegarwala F., Darcourt J., Graviss E. A., Giordano T. P., White A. C., Hamill R. J., Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005 19 4 399 406 2-s2.0-15944382687 (Pubitemid 40446186)
80. + T-regulatory cells and enhances their functional activity. Journal of Immunology 2005 175 12 7973 7980 2-s2.0-29144514700 (Pubitemid 41798358)
81. Lee C. W., Choi J. W., Chun J., Neurologyogical S1P signaling as an emerging mechanism of action of oral FTY720 (Fingolimod) in multiple sclerosis. Archives of Pharmacal Research 2010 33 10 1567 1574 2-s2.0-78449244305 10.1007/s12272-010-1008-5
82. Rigau V., Mania A., Befort P., Carlander B., Jonquet O., Lassmann H., Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology 2012 79 22 2214 2216
83. Marousi S., Travasarou M., Karageorgiou C. E., Gheuens S., Koralnik I. J., Simultaneous Pml-Iris after discontinuation of natalizumab in a patient with MS. Neurology 2012 79 21 2160
84. Wolf A. M., Eller K., Zeiser R., Dürr C., Gerlach U. V., Sixt M., Markut L., Gastl G., Rosenkranz A. R., Wolf D., The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo. Journal of Immunology 2009 183 6 3751 3760 2-s2.0-70349333237 10.4049/jimmunol.0901011
85. Suntharalingam G., Perry M. R., Ward S., Brett S. J., Castello-Cortes A., Brunner M. D., Panoskaltsis N., Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. New England Journal of Medicine 2006 355 10 1018 1028 2-s2.0-33748416499 10.1056/NEJMoa063842 (Pubitemid 44343545)
86. Buc M., The major histocompatibility complex in man. Folia Biologica 1995 41 3-4 119 122 2-s2.0-0029058317
87. Benesova Y., Vasku A., Stourac P., Hladikova M., Fiala A., Bednarik J., Association of HLA-DRB11501 tagging rs3135388 gene polymorphism with multiple sclerosis. Journal of Neuroimmunology 2013 255 1-2 92 96
88. Barun B., Bar-Or A., Treatment of multiple sclerosis with anti-CD20 antibodies. Clinical Immunology 2012 142 1 31 37
89. Ray A., Basu S., Williams C. B., Salzman N. H., Dittel B. N., A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand. Journal of Immunology 2012 188 7 3188 3198
90. Stashenko P., Nadler L. M., Hardy R., Schlossman S. F., Characterization of a human B lymphocyte-specific antigen. Journal of Immunology 1980 125 4 1678 1685 2-s2.0-0018949401 (Pubitemid 10018582)
91. Saidha S., Eckstein C., Calabresi P. A., New and emerging disease modifying therapies for multiple sclerosis. Annals of the New York Academy of Sciences 2012 1247 117 137
92. Rowan W. C., Hale G., Tite J. P., Brett S. J., Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. International Immunology 1995 7 1 69 77 2-s2.0-0028870425
93. Hederer R. A., Guntermann C., Miller N., Nagy P., Szollosi J., Damjanovich S., Hale G., Alexander D. R., The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells. International Immunology 2000 12 4 505 516 2-s2.0-0034033048 (Pubitemid 30199356)
94. Coles A. J., Cox A., Le Page E., Jones J., Trip S. A., Deans J., Seaman S., Miller D. H., Hale G., Waldmann H., Compston D. A., The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. Journal of Neurology 2006 253 1 98 108 2-s2.0-31544467633 10.1007/s00415-005-0934-5 (Pubitemid 43157395)
95. Coles A. J., Compston D. A. S., Selmaj K. W., Lake S. L., Moran S., Margolin D. H., Norris K., Tandon P. K., Alemtuzumab versus interferon beta-1a in early multiple sclerosis. New England Journal of Medicine 2008 359 17 1786 1801 2-s2.0-54949143968 10.1056/NEJMoa0802670
96. Thompson S. A. J., Jones J. L., Cox A. L., Compston D. A. S., Coles A. J., B-Cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. Journal of Clinical Immunology 2010 30 1 99 105 2-s2.0-77249114139 10.1007/s10875-009-9327-3
97. Coles A. J., Wing M., Smith S., Coraddu F., Greer S., Taylor C., Weetman A., Hale G., Chatterjee V. K., Waldmann H., Compston A., Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999 354 9191 1691 1695 2-s2.0-0033552391 10.1016/S0140-6736(99)02429-0 (Pubitemid 29533060)
98. Jones J. L., Anderson J. M., Phuah C. L., Fox E. J., Selmaj K., Margolin D., Lake S. L., Palmer J., Thompson S. J., Wilkins A., Webber D. J., Compston D. A., Coles A. J., Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 2010 133 8 2232 2247 2-s2.0-77957044257 10.1093/brain/awq176
99. Klotz L., Meuth S. G., Wiendl H., Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. Clinical Immunology 2012 142 1 25 30
100. Bielekova B., Daclizumab therapy for multiple sclerosis. Neurotherapeutics 2013 10 1 55 67
101. Martin R., Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clinical Immunology 2012 142 1 9 14
102. Brusko T., Bluestone J., Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation. European Journal of Immunology 2008 38 4 931 934 2-s2.0-44849118898 10.1002/eji.200738108
103. + Treg. European Journal of Immunology 2009 39 4 1108 1117 2-s2.0-65449122461 10.1002/eji.200839073
104. Nakayamada S., Takahashi H., Kanno Y., O'Shea J. J., Helper T cell diversity and plasticity. Current Opinion in Immunology 2012 24 3 297 302
105. Graber J. J., Dhib-Jalbut S., Biomarkers of disease activity in multiple sclerosis. Journal of the Neurological Sciences 2011 305 1-2 1 10 2-s2.0-79955678019 10.1016/j.jns.2011.03.026